Asymmetric siRNA targeting the bcl-2 gene inhibits the proliferation of cancer cells in vitro and in vivo

International Journal of Oncology

Volumn 42, Issue 1, 2013, Pages 253-260

  Yin, Yan ^a   Chen, Xu ^a   Zhang, Chang Dong ^a   Liu, Pei Feng ^b   Duan, You Rong ^b   Fan, Yan Rong ^c   Wu, Zhi Wei ^a   Fu, Geng Feng ^d   Wang, Jian Jun ^a   Xu, Gen Xing ^a,e  

^a NANJING UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^e Jiangsu Research Center for Gene Pharmaceutical Engineering and Technology   (China)

Author keywords

Asymmetric siRNA; Bcl 2; Cancer gene therapy; Small interfering RNAs

Indexed keywords

17 BP ASIRNA; ANTINEOPLASTIC AGENT; PROTEIN BCL 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICELLE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN TARGETING; RNA STABILITY; RNA SYNTHESIS; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; FLOW CYTOMETRY; GENE SILENCING; HELA CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENE PROTEINS C-BCL-2; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84873661833     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1691     Document Type: Article

References (35)

1. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998. (Pubitemid 28406819)
2. Kaiser U, Schilli M, Haag U, Neumann K, Kreipe H, Kogan E and Havemann K: Expression of bcl 2 protein in small cell lung cancer. Lung Cancer 15: 31-40, 1996. (Pubitemid 26337007)
3. Kobayashi S, Iwase H, Ito Y, et al: Clinical significance of bcl 2 gene expression in human breast cancer tissues. Breast Cancer Res Treat 42: 173-181, 1997. (Pubitemid 27056778)
4. Kaklamanis L, Savage A, Whitehouse R, et al: bcl-2 protein expression: association with p53 and prognosis in colorectal cancer. Br J Cancer 77: 1864-1869, 1998. (Pubitemid 28254625)
5. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55: 237-241, 1995.
6. Bronner MP, Culin C, Reed JC and Futh EE: The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 146: 20-26, 1995.
7. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S and Kamidono S: Overexpression of bcl-2 enhances metastatic potential of human bladder cancer cells. Br J Cancer 79: 1651-1656, 1999. (Pubitemid 29132285)
8. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001. (Pubitemid 32494397)
9. Zamore PD, Tuschl T, Sharp PA and Bartel DP: RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101: 25-33, 2000.
10. Jackson AL and Linsley PS: Noise amidst the silence: off-target effects of siRNAs? Trends Genet 20: 521-524, 2004. (Pubitemid 39314555)
11. Clark PR, Pober JS and Kluger MS: Knockdown of TNFR1 by the sense strand of an ICAM-1 siRNA: dissection of an off-target effect. Nucleic Acids Res 36: 1081-1097, 2008. (Pubitemid 351330927)
12. Sun X, Rogoff HA and Li CJ: Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat Biotechnol 26: 1379-1382, 2008.
13. Chang CI, Yoo JW, Hong SW, et al: Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol Ther 17: 725-732, 2009.
14. Jo S, Hong SW, Yoo JW, Lee CH, Kim S, Kim S and Lee DK: Selection and optimization of asymmetric siRNA targeting the human c-MET gene. Mol Cells 32: 543-548, 2011.
15. Watts JK, Deleavey GF and Damha MJ: Chemically modified siRNA: tools and applications. Drug Discov Today 13: 842-855, 2008.
16. Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA and Corey DR: RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42: 7967-7975, 2003. (Pubitemid 36807714)
17. Amarzguioui M, Holen T, Babaie E and Prydz H: Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 31: 589-595, 2003. (Pubitemid 36175948)
18. Love KT, Mahon KP, Levins CG, et al: Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107: 1864-1869, 2010.
19. Park K, Lee MY, Kim KS and Hahn SK: Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate. Biomaterials 31: 5258-5265, 2010.
20. Davis ME, Zuckerman JE, Choi CH, et al: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 1067-1070, 2010.
21. Fu GF, Lin XH, Han QW, et al: RNA interference remarkably suppresses bcl-2 gene expression in cancer cells in vitro and in vivo. Cancer Biol Ther 4: 822-829, 2005.
22. Guo JJ, Yin Y, Zhang CD, Wang JJ and Xu GX: Antitumor effects of liposome-mediated siRNA and asymmetric shorter-duplex siRNA suppressing VEGF gene expression. Pharm Clin Res 19: 489-494, 2011.
23. Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N and Zamore PD: Asymmetry in the assembly of the RNAi enzyme complex. Cell 115: 199-208, 2003. (Pubitemid 37329583)
24. Ameres SL, Martinez J and Schroeder R: Molecular basis for target RNA recognition and cleavage by human RISC. Cell 130: 101-112, 2007. (Pubitemid 47031315)
25. Sano M, Sierant M, Miyagishi M, Nakanishi M, Takagi Y and Sutou S: Effect of asymmetric terminal structures of short RNA duplexes on the RNA interference activity and strand selection. Nucleic Acids Res 36: 5812-5821, 2008.
26. White PJ: Barriers to successful delivery of short interfering RNA after systemic administration. Clin Exp Pharmacol Physiol 35: 1371-1376, 2008.
27. Aagaard L and Rossi JJ: RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59: 75-86, 2007. (Pubitemid 46770900)
28. Chiu YL and Rana TM: siRNA function in RNAi: a chemical modification analysis. RNA 9: 1034-1048, 2003. (Pubitemid 37093614)
29. Lorenz C, Hadwiger P, John M, Vornlocher HP and Unverzagt C: Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 14: 4975-4977, 2004. (Pubitemid 39165605)
30. Soutschek J, Akinc A, Bramlage B, et al: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178, 2004. (Pubitemid 39545841)
31. Maeda H, Wu J, Sawa T, Matsumura Y and Hori K: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65: 271-284, 2000. (Pubitemid 30122932)
32. Maeda H, Bharate GY and Daruwalla J: Polymeric drugs for efficient tumor-targeted drug delivery based on EPR effect. Eur J Pharm Biopharm 71: 409-419, 2009.
33. Zhao H, Jutila A, Nurminen T, Wickström SA, Keski Oja J and Kinnunen PK: Binding of endostatin to phosphatidylserine-containing membranes and formation of amyloid-like fibers. Biochemistry 44: 2857-2863, 2005. (Pubitemid 40293661)
34. Ran S, Downes A and Thorpe PE: Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 62: 6132-6140, 2002. (Pubitemid 35244462)
35. Utsugi T, Schroit AJ, Connor J, Bucana CD and Fidler IJ: Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 51: 3062-3066, 1991.